<DOC>
	<DOCNO>NCT00893477</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , GM-CSF , may stimulate immune system different way stop cancer cell grow . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving GM-CSF together rituximab may kill cancer cell . PURPOSE : This phase II trial study well give GM-CSF together rituximab work treat patient previously untreated follicular non-Hodgkin lymphoma .</brief_summary>
	<brief_title>GM-CSF Rituximab Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate clinical efficacy sargramostim ( GM-CSF ) rituximab , term overall objective complete partial response rate , patient previously untreated follicular non-Hodgkin lymphoma . Secondary - Evaluate time progression patient treat regimen . - Evaluate overall survival patient treat regimen . - Evaluate duration response patient treat regimen . - Evaluate safety profile regimen patient . - Evaluate influence FcγR polymorphisms clinical response . - Monitor FcγR-expressing cell peripheral blood treatment . - Monitor molecular biological marker bcl2 [ ( 14 ; 18 ) ] peripheral blood bone marrow . OUTLINE : This multicenter study . - Induction therapy : Patients receive sargramostim ( GM-CSF ) subcutaneously ( SC ) day 1-5 rituximab IV day 1 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . - Maintenance therapy : Patients receive GM-CSF SC day 1-5 rituximab IV day 1 . Treatment repeat every 8 week 12 course absence disease progression unacceptable toxicity . Blood bone marrow sample collect baseline periodically study analysis bcl2 rearrangement PCR assay ; FcγR expression immunophenotyping ; FcγR polymorphism . After completion study therapy , patient follow every 3 month 1 year every 6 month 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically immunophenotypically confirm CD20+ follicular lymphoma accord WHO classification Grade 13a disease Stage IIIV disease Nonbulky disease Must undergone initial nodal biopsy within past 4 month At least 1 measurable lesion Low tumorburden , define follow GELF criterion : Nodal extranodal tumor mass ( diameter &lt; 7 cm ) No systemic B symptoms No increased LDH β2 microglobulinemia No substantial splenic enlargement No serous effusion No compression syndrome PATIENT CHARACTERISTICS : ECOG performance status 01 Negative pregnancy test Fertile patient must use effective contraception No active hepatitis PRIOR CONCURRENT THERAPY : No prior treatment , include steroid radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage II grade 1 follicular lymphoma</keyword>
	<keyword>stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>